 CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 GLOBE NEWSWIRE -- BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay or the Company, a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its second quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In Webcast Information:Date: Wednesday, August 12, 2020 Time:8:30 AM Eastern Time United States:877-407-3982 Israel:1 809 406 247 International:201-493-6780 Conference ID:13706952 Webcast: The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, Please access the Companys website at least 10 minutes ahead of the conference call to register.About BrainsWay BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation Deep TMS technology for the treatment of major depressive disorder MDD and obsessive-compulsive disorder OCD, for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration FDA in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.Forward Looking Statements Any forward-looking statements are subject to risks and uncertainties such as those described in BrainsWays periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts: BrainsWay Judy Huber SVP and Chief Financial Officer Bob Yedid LifeSci Advisors 646-597-6989 